Metis Global Partners LLC Cuts Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Metis Global Partners LLC reduced its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 2.6% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 4,572 shares of the biotechnology company’s stock after selling 124 shares during the quarter. Metis Global Partners LLC’s holdings in Axon Enterprise were worth $1,181,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AXON. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Axon Enterprise by 8.9% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 7,716 shares of the biotechnology company’s stock worth $1,535,000 after buying an additional 630 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in Axon Enterprise by 2.3% during the third quarter. Mackenzie Financial Corp now owns 6,292 shares of the biotechnology company’s stock valued at $1,208,000 after purchasing an additional 141 shares during the last quarter. Advisor Partners II LLC lifted its holdings in Axon Enterprise by 3.5% during the third quarter. Advisor Partners II LLC now owns 3,407 shares of the biotechnology company’s stock valued at $678,000 after purchasing an additional 115 shares during the last quarter. Park Avenue Securities LLC purchased a new stake in Axon Enterprise during the third quarter valued at about $828,000. Finally, TD Asset Management Inc lifted its holdings in Axon Enterprise by 3.0% during the third quarter. TD Asset Management Inc now owns 22,342 shares of the biotechnology company’s stock valued at $4,446,000 after purchasing an additional 645 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Stock Down 0.3 %

AXON stock opened at $311.86 on Thursday. The company has a current ratio of 3.00, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42. The company’s 50 day moving average is $310.82 and its 200 day moving average is $267.44. The stock has a market cap of $23.53 billion, a price-to-earnings ratio of 135.59 and a beta of 0.91. Axon Enterprise, Inc. has a 1-year low of $175.37 and a 1-year high of $329.87.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Monday, May 6th. The biotechnology company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.20. The company had revenue of $460.74 million for the quarter, compared to analysts’ expectations of $441.57 million. Axon Enterprise had a net margin of 11.14% and a return on equity of 14.11%. Axon Enterprise’s revenue for the quarter was up 34.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.51 earnings per share. Sell-side analysts predict that Axon Enterprise, Inc. will post 2.44 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on AXON. Barclays upped their price objective on shares of Axon Enterprise from $308.00 to $381.00 and gave the company an “overweight” rating in a report on Wednesday. StockNews.com downgraded shares of Axon Enterprise from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. Craig Hallum upped their price objective on shares of Axon Enterprise from $325.00 to $370.00 and gave the company a “buy” rating in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $400.00 price target on shares of Axon Enterprise in a research report on Tuesday. Finally, Argus started coverage on Axon Enterprise in a research report on Wednesday, March 13th. They set a “buy” rating and a $380.00 price target on the stock. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and an average price target of $333.08.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.